Phathom Pharmaceuticals Reports Q3 Net Revenue of $49.5 Million
Reuters
Oct 30
<a href="https://laohu8.com/S/PHAT">Phathom Pharmaceuticals</a> Reports Q3 Net Revenue of $49.5 Million
Phathom Pharmaceuticals Inc. reported net revenues of $49.5 million for the third quarter of 2025, reflecting a 25% increase compared to previous periods. The company updated its full year 2025 net revenue guidance to a range of $170 million to $175 million, up from the previous range of $165 million to $175 million. In terms of business developments, Phathom Pharmaceuticals implemented a new GI-focused call point strategy and realigned its sales territories to concentrate on gastrointestinal accounts. The company rolled out new target lists that now include nearly all gastrointestinal specialists, as part of efforts to generate greater depth with GI writers. According to IQVIA data, there are approximately 24,000 annual PPI writers and about 20 million annual PPI prescriptions as of October 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phathom Pharmaceuticals Inc. published the original content used to generate this news brief on October 30, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.